BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10598047)

  • 1. Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185).
    Kucuk O; Pandya KJ; Skeel RT; Hochster H; Abeloff MD
    Breast Cancer Res Treat; 1999 Sep; 57(2):201-6. PubMed ID: 10598047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study.
    Nolè F; Munzone E; Mandalà M; Catania C; Orlando L; Zampino MG; Minchella I; Colleoni M; Peruzzotti G; Marrocco E; Goldhirsch A
    Ann Oncol; 2001 Jan; 12(1):95-100. PubMed ID: 11249057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer.
    Klaassen U; Wilke H; Weyhofen R; Harstrick A; Eberhardt W; Müller C; Korn M; Hanske M; Diergarten K; Seeber S
    Anticancer Drugs; 1998 Mar; 9(3):203-7. PubMed ID: 9625430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study.
    Klaassen U; Wilke H; Müller C; Borquez D; Harstrick A; Seeber S
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-58-S17-60. PubMed ID: 9374095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer.
    Klaassen U; Wilke H; Müller C; Borquez D; Korn M; Achterrath W; Harstrick A; Diergarten K; Seeber S
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):38-40. PubMed ID: 9144690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
    Kucuk O; Shevrin DH; Pandya KJ; Bonomi PD
    Am J Clin Oncol; 2000 Aug; 23(4):371-5. PubMed ID: 10955866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
    Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
    Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
    Vokes EE; Schilsky RL; Weichselbaum RR; Guaspari A; Guarnieri CM; Whaling SM; Panje WR
    Cancer; 1989 Mar; 63(6 Suppl):1048-53. PubMed ID: 2783881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.
    Bonnefoi H; Smith IE; O'Brien ME; Seymour MT; Powles TJ; Allum WH; Ebbs S; Baum M
    Br J Cancer; 1996 Feb; 73(3):391-6. PubMed ID: 8562348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
    Chi KH; Chan WK; Shu CH; Law CK; Chen SY; Yen SH; Chen KY
    Cancer; 1995 Dec; 76(11):2186-92. PubMed ID: 8635020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.
    Jones AL; Smith IE; O'Brien ME; Talbot D; Walsh G; Ramage F; Robertshaw H; Ashley S
    J Clin Oncol; 1994 Jun; 12(6):1259-65. PubMed ID: 8201387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type.
    Taamma A; Fandi A; Azli N; Wibault P; Chouaki N; Hasbini A; Couteau C; Armand JP; Cvitkovic E
    Cancer; 1999 Oct; 86(7):1101-8. PubMed ID: 10506692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancer.
    Tolcher AW; Gelmon KA
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):28-32. PubMed ID: 7638639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.